These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37378536)

  • 21. Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients.
    Mrzljak A; Jureković Ž; Pavičić-Šarić J; Stevanović V; Tabain I; Hruškar Ž; Mikulić D; Barbić L; Vilibić-Čavlek T
    Biochem Med (Zagreb); 2021 Oct; 31(3):030901. PubMed ID: 34658649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab.
    Aihara R; Umemura K; Katada Y; Nakagawa S; Kobayashi T; Hatano E; Date H; Nagao M; Terada T
    J Infect Chemother; 2024 Dec; 30(12):1222-1227. PubMed ID: 38777151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19.
    Kapur R; Okumura K; Feola N; Keller M; Dhand A
    Cureus; 2023 May; 15(5):e38867. PubMed ID: 37313067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
    Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic.
    Srinivasan V; Weinstein SE; Bhimani A; Clemons NC; Dinolfo M; Shin CS; Grier J; Lopez A; Braggs J; Boucher J; Batiste QN; Garner OB; Yang S; Vijayan T
    PLoS One; 2022; 17(12):e0278394. PubMed ID: 36454767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
    Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
    Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
    Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
    Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
    Ahearn AJ; Thin Maw T; Mehta R; Emamaullee J; Kim J; Blodget E; Kahn J; Sher L; Genyk Y
    Transplantation; 2022 Feb; 106(2):e153-e157. PubMed ID: 34519680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients.
    Huh K; Kang M; Kim YE; Choi Y; An SJ; Seong J; Go MJ; Kang JM; Jung J
    J Infect Dis; 2024 Apr; 229(4):1026-1034. PubMed ID: 38097377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARDS in solid organ transplant recipients hospitalized for COVID-19 based on the 2023 new definition.
    Tang J; Zhou Y; Gong L; Deng J; Yuan Y; Zhong Y; Li J; Wang G
    Heart Lung; 2024; 66():103-107. PubMed ID: 38604053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
    Pereira MR; Mohan S; Cohen DJ; Husain SA; Dube GK; Ratner LE; Arcasoy S; Aversa MM; Benvenuto LJ; Dadhania DM; Kapur S; Dove LM; Brown RS; Rosenblatt RE; Samstein B; Uriel N; Farr MA; Satlin M; Small CB; Walsh TJ; Kodiyanplakkal RP; Miko BA; Aaron JG; Tsapepas DS; Emond JC; Verna EC
    Am J Transplant; 2020 Jul; 20(7):1800-1808. PubMed ID: 32330343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
    Romero A; Laurent C; Lebourg L; Lemée V; Hanoy M; Le Roy F; Grange S; Lemoine M; Guerrot D; Bertrand D
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543747
    [No Abstract]   [Full Text] [Related]  

  • 33. The effects of COVID-19 on pediatric and adult solid organ transplant recipients and the emergence of telehealth.
    Raina R; Shah R; Marks SD; Johnson JN; Nied M; Bhatt GC; Bonham CA; Datla N; Sethi SK; Bartosh SM
    Pediatr Transplant; 2023 Jun; 27(4):e14490. PubMed ID: 36879358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era.
    Massie AB; Werbel WA; Avery RK; Po-Yu Chiang T; Snyder JJ; Segev DL
    Am J Transplant; 2022 Aug; 22(8):2077-2082. PubMed ID: 35294799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
    Dhand A; Razonable RR
    Curr Transplant Rep; 2022; 9(1):26-34. PubMed ID: 35070639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Relative Risk of COVID-19 in Solid Organ Transplant Recipients Over Waves of the Pandemic.
    Vinson AJ; Anzalone AJ; Schissel M; Dai R; Agarwal G; Lee SB; Olex A; Mannon RB
    Transpl Int; 2024; 37():13351. PubMed ID: 39310711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study.
    Jin H; Geiger C; Jessop N; Pedotti R; Raposo C; Whitley L; Brown JS; Muros-Le Rouzic E
    Mult Scler Relat Disord; 2023 Nov; 79():104943. PubMed ID: 37716211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
    Yetmar ZA; Yao JD; Razonable RR
    J Med Virol; 2023 Jun; 95(6):e28885. PubMed ID: 37334976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
    Hedvat J; Lange NW; Salerno DM; DeFilippis EM; Kovac D; Corbo H; Chen JK; Choe JY; Lee JH; Anamisis A; Jennings DL; Codispodo G; Shertel T; Brown RS; Pereira MR
    Am J Transplant; 2022 Nov; 22(11):2682-2688. PubMed ID: 35801839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the Omicron variant truly less virulent in solid organ transplant recipients?
    Anjan S; Khatri A; Viotti JB; Cheung T; Garcia LAC; Simkins J; Loebe M; Phancao A; O'Brien CB; Sinha N; Ciancio G; Vianna RM; Andrews D; Abbo LM; Guerra G; Natori Y
    Transpl Infect Dis; 2022 Dec; 24(6):e13923. PubMed ID: 35915957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.